| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701563 | Journal of Thoracic Oncology | 2017 | 10 Pages |
Abstract
The ALK (D5F3) CDx assay is a stand-alone companion diagnostic test for identification of patients for treatment with crizotinib. This automated assay provides an effective option to accurately and rapidly identify patients with ALK-positive NSCLC. The simple binary scoring algorithm results in high reader-to-reader precision.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Trish BS, Crystal MPH, Alice BS, June MD, Shalini MD, James MD, Kim MD, Zoran MD, Steffan N. MD, PhD, Isabell PhD, Abigail PhD, Penny MBA,